KALA BIO launches AI infrastructure platform; licenses Researgency from Younet AI

KALA BIO, Inc.

Exclusive worldwide license to Researgency platform for biotech field; initial 12-month term with renewal options.
Consideration includes up to $530k cash and issuance of 5 million shares of KALA common stock per term.
Company holds an irrevocable option to acquire Younet AI for $55 million, exercisable during the term.
Strategic pivot: KALA will deploy on-premises, data-sovereign AI for biotech clients targeting recurring revenue.
KALA will first deploy on its own MSC-S and KPI-012 data; preliminary findings expected in 12 months.

item 1.01 item 3.02 item 7.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001829126-26-001911
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2026-03-04T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.170346+00:00
generated_at: 2026-05-15T21:38:26.902714+00:00
sec_items: ["1.01", "3.02", "7.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001829126-26-001911
json_url: https://secwatch.observer/filing/0001829126-26-001911.json
markdown_url: https://secwatch.observer/filing/0001829126-26-001911.md
text_url: https://secwatch.observer/filing/0001829126-26-001911.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000182912626001911/0001829126-26-001911-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000182912626001911/kalabio_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001829126-26-001911

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.